Compare Stocks: ALVO, CGON, RYTM, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.81 -0.5%	$4.38	$2.94 ▼ $9.05	$1.75B	0.22	726,273 shs	773,966 shs
CGON CG Oncology	$73.36 -5.6%	$74.30	$35.64 ▼ $80.97	$6.50B	0.24	1.10 million shs	830,942 shs
ORKA Oruka Therapeutics	$89.93 -4.9%	$96.72	$14.89 ▼ $115.51	$5.95B	-0.34	1.10 million shs	1.99 million shs
RYTM Rhythm Pharmaceuticals	$98.24 -1.0%	$106.85	$74.50 ▼ $122.20	$6.73B	1.97	755,283 shs	696,408 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.68%	+16.33%	+31.83%	+57.62%	-27.09%
CGON CG Oncology	-0.65%	+7.15%	-2.59%	+13.13%	+109.88%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%
RYTM Rhythm Pharmaceuticals	+0.45%	+2.58%	-9.75%	-7.70%	+0.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.81 -0.5%	$4.38	$2.94 ▼ $9.05	$1.75B	0.22	726,273 shs	773,966 shs
CGON CG Oncology	$73.36 -5.6%	$74.30	$35.64 ▼ $80.97	$6.50B	0.24	1.10 million shs	830,942 shs
ORKA Oruka Therapeutics	$89.93 -4.9%	$96.72	$14.89 ▼ $115.51	$5.95B	-0.34	1.10 million shs	1.99 million shs
RYTM Rhythm Pharmaceuticals	$98.24 -1.0%	$106.85	$74.50 ▼ $122.20	$6.73B	1.97	755,283 shs	696,408 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.68%	+16.33%	+31.83%	+57.62%	-27.09%
CGON CG Oncology	-0.65%	+7.15%	-2.59%	+13.13%	+109.88%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%
RYTM Rhythm Pharmaceuticals	+0.45%	+2.58%	-9.75%	-7.70%	+0.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$8.50	46.43% Upside
CGON CG Oncology	2.73	Moderate Buy	$87.78	19.84% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	51.85% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.67	45.47% Upside

Current Analyst Ratings Breakdown

Latest ALVO, CGON, RYTM, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/17/2026	RYTM Rhythm Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
9/16/2026	ALVO Alvotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Overweight	$4.00 ➝ $8.00
9/14/2026	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$133.00
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$588.90M	2.98	$0.22 per share	26.98	($0.94) per share	-6.18
CGON CG Oncology	$4.04M	1,607.08	N/A	N/A	$9.33 per share	7.85
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	34.92	N/A	N/A	$2.08 per share	46.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	24.19	N/A	-36.31%	-11.92%	-11.73%	11/11/2026 (Estimated)
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest ALVO, CGON, RYTM, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.22	$103.00 million	$106.00 million
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
CGON CG Oncology	N/A	22.22	22.20
ORKA Oruka Therapeutics	N/A	38.51	38.51
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CGON CG Oncology	26.56%
ORKA Oruka Therapeutics	56.44%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	N/A
CGON CG Oncology	4.80%
ORKA Oruka Therapeutics	23.49%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

ALVO, CGON, RYTM, and ORKA Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. Announces Health Canada Approval Of IMCIVREE (Setmelanotide) For Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With ...

September 23 at 5:59 AM | marketscreener.comM

Health Canada approves Rhythm's Imcivree for hypothalamic obesity

September 23 at 5:59 AM | streetinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with ...

September 22 at 8:47 AM | markets.businessinsider.com

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

September 22 at 8:00 AM | globenewswire.com

325,470 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Bank of America Corp DE

September 22 at 3:04 AM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Wolfe Research

September 19, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)

September 17, 2026 | theglobeandmail.com

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

September 17, 2026 | marketscreener.comM

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 5.3% After Insider Selling

September 17, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Leerink Partners

September 16, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

September 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO David Meeker Sells 50,000 Shares

September 15, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

September 15, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners

September 14, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

September 14, 2026 | marketbeat.com

Head-To-Head Survey: Generate Biomedicines (NASDAQ:GENB) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM)

September 12, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology Meeting

September 11, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, CGON, RYTM, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

$5.81 -0.03 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$5.82 +0.01 (+0.17%)

As of 06:49 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

CG Oncology NASDAQ:CGON

$73.36 -4.38 (-5.63%)

Closing price 04:00 PM Eastern

Extended Trading

$73.36 0.00 (-0.01%)

As of 04:54 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Oruka Therapeutics NASDAQ:ORKA

$89.93 -4.62 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$89.62 -0.32 (-0.35%)

As of 06:28 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rhythm Pharmaceuticals NASDAQ:RYTM

$98.24 -1.03 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$97.34 -0.91 (-0.92%)

As of 06:53 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVO, CGON, RYTM, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVO, CGON, RYTM, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVO, CGON, RYTM, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, CGON, RYTM, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

CG Oncology NASDAQ:CGON

Oruka Therapeutics NASDAQ:ORKA

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVO, CGON, RYTM, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVO, CGON, RYTM, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVO, CGON, RYTM, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, CGON, RYTM, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

CG Oncology NASDAQ:CGON

Oruka Therapeutics NASDAQ:ORKA

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools